Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

Similar articles for PubMed (Select 24196384)

1.

Therapeutic drug monitoring in rheumatic diseases: utile or futile?

Stamp LK, Barclay M.

Rheumatology (Oxford). 2014 Jun;53(6):988-97. Review.

PMID:
24196384
2.

An audit of a therapeutic drug monitoring service for allopurinol therapy.

Kannangara DR, Ramasamy SN, Ray JE, Jones G, Graham GG, Williams KM, Day RO.

Ther Drug Monit. 2013 Dec;35(6):863-6. doi: 10.1097/FTD.0b013e318299920a.

PMID:
24263644
3.

The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics?

Stamp L, Roberts R, Kennedy M, Barclay M, O'Donnell J, Chapman P.

Biomed Pharmacother. 2006 Dec;60(10):678-87. Epub 2006 Oct 20. Review.

PMID:
17071051
4.

Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.

Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.

Clin Pharmacol Ther. 2011 Sep;90(3):392-8. doi: 10.1038/clpt.2011.113. Epub 2011 Jul 27.

PMID:
21796116
5.

Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.

Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL.

Rheumatology (Oxford). 2002 Apr;41(4):430-9.

6.

[Pharmacological management of inflammatory rheumatic conditions].

Bannwarth B.

Therapie. 2011 Sep-Oct;66(5):377-81. doi: 10.2515/therapie/2011055. Epub 2011 Oct 27. Review. French.

PMID:
22031680
7.

Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.

Panomvana D, Sripradit S, Angthararak S.

J Clin Rheumatol. 2008 Feb;14(1):6-11. doi: 10.1097/RHU.0b013e318164dceb.

PMID:
18431090
8.

A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate.

Hobl EL, Jilma B, Erlacher L, Duhm B, Mustak M, Bröll H, Högger P, Rizovski B, Mader RM.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2):156-63. Epub 2012 Apr 13.

PMID:
22152098
10.

Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001).

Furst DE, Keystone EC, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, Burmester GR, Crofford LJ, Kavanaugh A.

Ann Rheum Dis. 2001 Nov;60 Suppl 3:iii2-5. Review.

11.

The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.

Heiberg MS, Koldingsnes W, Mikkelsen K, Rødevand E, Kaufmann C, Mowinckel P, Kvien TK.

Arthritis Rheum. 2008 Feb 15;59(2):234-40. doi: 10.1002/art.23333.

PMID:
18240258
12.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

13.

The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.

Finckh A, Dehler S, Gabay C; SCQM doctors.

Ann Rheum Dis. 2009 Jan;68(1):33-9. doi: 10.1136/ard.2007.085696. Epub 2008 Jan 29.

PMID:
18230627
14.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
15.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

16.

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register.

Ann Rheum Dis. 2011 Apr;70(4):583-9. doi: 10.1136/ard.2010.139774. Epub 2011 Feb 17.

17.

The use of conventional disease-modifying anti-rheumatic drugs in established RA.

Jurgens MS, Jacobs JW, Bijlsma JW.

Best Pract Res Clin Rheumatol. 2011 Aug;25(4):523-33. doi: 10.1016/j.berh.2011.10.006. Review.

PMID:
22137922
18.
19.

Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.

Hjeltnes G, Hollan I, Førre O, Wiik A, Lyberg T, Mikkelsen K, Agewall S.

Clin Exp Rheumatol. 2013 May-Jun;31(3):415-21. Epub 2013 Mar 4.

PMID:
23465067
20.

Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.

Katchamart W, Trudeau J, Phumethum V, Bombardier C.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD008495. doi: 10.1002/14651858.CD008495. Review.

PMID:
20393970
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk